Literature DB >> 33939386

Is Microsatellite Status Associated With Prognosis in Stage II Colon Cancer With High-Risk Features?

Paul M Cavallaro1, Caitlin Stafford, Christy E Cauley, David L Berger, Liliana Bordeianou, Hiroko Kunitake, Todd Francone, Rocco Ricciardi.   

Abstract

BACKGROUND: The influence of microsatellite instability on prognosis in high-risk stage II colon cancer is unknown.
OBJECTIVE: This study aimed to investigate the relationship between microsatellite instability and overall survival in high-risk stage II colon cancer.
DESIGN: This is a retrospective review of the National Cancer Database from 2010 to 2016. SETTINGS: This study included national cancer epidemiology data from the American College of Surgeons Commission on Cancer. PATIENTS: Included were 16,788 patients with stage II colon adenocarcinoma and known microsatellite status (1709 microsatellite unstable). MAIN OUTCOME MEASURES: The primary outcome measured was overall survival.
RESULTS: Microsatellite unstable cancers with high-risk features had significantly better overall survival than microsatellite stable cancers with high-risk features (5-year survival 80% vs 72%, p = 0.01), and had survival equivalent to microsatellite stable cancers with low-risk features (5-year survival, 80%). When stratified by specific high-risk features, patients with lymphovascular invasion, perineural invasion, or high-grade histology had overall survival similar to patients without these features, only in microsatellite unstable cancers. However, patients with high-risk features of T4 stage, positive margins, and <12 lymph nodes saw no survival benefit based on microsatellite status. This was confirmed on multivariable Cox regression modeling. A subgroup analysis of patients who did not receive chemotherapy similarly demonstrated that microsatellite unstable cancers with lymphovascular invasion, perineural invasion, or high-grade histology had overall survival similar to microsatellite unstable cancers without those features. LIMITATIONS: The study is limited by the lack of specific clinical data and potential treatment bias.
CONCLUSIONS: In microsatellite unstable cancers, lymphovascular invasion, perineural invasion, and high-grade histology are not associated with worse overall survival, even when deferring adjuvant chemotherapy. These data support National Comprehensive Cancer Network recommendations to forego chemotherapy in stage II cancers with microsatellite instability and these features. In contrast, some high-risk features were associated with worse survival despite microsatellite unstable biology, and therapies to improve survival need to be explored. See Video Abstract at http://links.lww.com/DCR/B500. ¿EL ESTADO MICROSATÉLITE ESTÁ ASOCIADO CON EL PRONÓSTICO EN EL CÁNCER DE COLON EN ESTADIO II CON CARACTERÍSTICAS DE ALTO RIESGO: Se desconoce la influencia de la inestabilidad microsatélite en el pronóstico del cáncer de colon en estadio II de alto riesgo.Investigar la relación entre la inestabilidad microsatélite y la supervivencia general en el cáncer de colon en estadio II de alto riesgo.Revisión retrospectiva de la base de datos nacional del cáncer de 2010 a 2016.Este estudio incluyó datos nacionales de epidemiología del cáncer de la Comisión de Cáncer del Colegio Americano de Cirujanos.16,788 pacientes con adenocarcinoma de colon en estadio II y estado microsatélite conocido (1,709 microsatélite inestables).Supervivencia global.Los cánceres microsatélite inestables con características de alto riesgo tuvieron una supervivencia general significativamente mejor que los cánceres microsatélite estables con características de alto riesgo (supervivencia a 5 años 80% vs 72%, p = 0.01), y tuvieron una supervivencia equivalente a los cánceres microsatélite estables con características de bajo riesgo (supervivencia a 5 años 80%). Al estratificar por características específicas de alto riesgo, los pacientes con invasión linfovascular, invasión perineural o histología de alto grado tuvieron una supervivencia general similar a la de los pacientes sin estas características, solo en cánceres microsatélite inestables. Sin embargo, los pacientes con características de alto riesgo en estadio T4, márgenes positivos y <12 ganglios linfáticos no tuvieron ningún beneficio de supervivencia basado en el estado de microsatélites. Esto se confirmó en un modelo de regresión de Cox multivariable. Un análisis de subgrupos de pacientes que no recibieron quimioterapia demostró de manera similar que los cánceres microsatélite inestables con invasión linfovascular, invasión perineural o histología de alto grado tenían una supervivencia general similar a los cánceres microsatélite inestables sin esas características.El estudio está limitado por la falta de datos clínicos específicos y el posible sesgo de tratamiento.En los cánceres microsatélite inestables, la invasión linfovascular, la invasión perineural y la histología de alto grado no se asocian con una peor sobrevida general, incluso cuando se aplaza la quimioterapia adyuvante. Estos datos respaldan las recomendaciones de la National Comprehensive Cancer Network de omitir la quimioterapia en los cánceres en estadio II con inestabilidad microsatélite y estas características. Por el contrario, algunas características de alto riesgo se asociaron con una peor supervivencia a pesar de la biología microsatélite inestable, y es necesario considerar las terapias para mejorar la supervivencia.Consulte Video Resumen en http://links.lww.com/DCR/B500. (Traducción-Dr. Jorge Silva Velazco).

Entities:  

Mesh:

Year:  2021        PMID: 33939386      PMCID: PMC8097721          DOI: 10.1097/DCR.0000000000001914

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  22 in total

1.  Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer.

Authors:  R Gryfe; H Kim; E T Hsieh; M D Aronson; E J Holowaty; S B Bull; M Redston; S Gallinger
Journal:  N Engl J Med       Date:  2000-01-13       Impact factor: 91.245

2.  Clinical Implications of Mismatch Repair Status in Patients With High-risk Stage II Colon Cancer.

Authors:  Jin Ho Baek; Jong Gwang Kim; Dong Won Baek; Byung Woog Kang; Soo Jung Lee; Hye Jin Kim; Su Yeon Park; Jun Seok Park; Gyu Seog Choi
Journal:  In Vivo       Date:  2019 Mar-Apr       Impact factor: 2.155

3.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer.

Authors:  T Watanabe; T T Wu; P J Catalano; T Ueki; R Satriano; D G Haller; A B Benson; S R Hamilton
Journal:  N Engl J Med       Date:  2001-04-19       Impact factor: 91.245

4.  BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics.

Authors:  Amanda I Phipps; Daniel D Buchanan; Karen W Makar; Andrea N Burnett-Hartman; Anna E Coghill; Michael N Passarelli; John A Baron; Dennis J Ahnen; Aung Ko Win; John D Potter; Polly A Newcomb
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-08-16       Impact factor: 4.254

5.  High-Risk Stage II Colon Cancer: Not All Risks Are Created Equal.

Authors:  Blake D Babcock; Mayada A Aljehani; Brice Jabo; Audrey H Choi; John W Morgan; Matthew J Selleck; Fabrizio Luca; Elizabeth Raskin; Mark E Reeves; Carlos A Garberoglio; Sharon S Lum; Maheswari Senthil
Journal:  Ann Surg Oncol       Date:  2018-04-19       Impact factor: 5.344

Review 6.  Postoperative chemotherapy improves survival in patients with resected high-risk Stage II colorectal cancer: results of a systematic review and meta-analysis.

Authors:  C Simillis; H K S I Singh; T Afxentiou; S Mills; O J Warren; J J Smith; P Riddle; M Adamina; D Cunningham; P P Tekkis
Journal:  Colorectal Dis       Date:  2020-02-27       Impact factor: 3.788

7.  Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

Authors:  Daniel J Sargent; Silvia Marsoni; Genevieve Monges; Stephen N Thibodeau; Roberto Labianca; Stanley R Hamilton; Amy J French; Brian Kabat; Nathan R Foster; Valter Torri; Christine Ribic; Axel Grothey; Malcolm Moore; Alberto Zaniboni; Jean-Francois Seitz; Frank Sinicrope; Steven Gallinger
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

8.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

Authors:  Christine M Ribic; Daniel J Sargent; Malcolm J Moore; Stephen N Thibodeau; Amy J French; Richard M Goldberg; Stanley R Hamilton; Pierre Laurent-Puig; Robert Gryfe; Lois E Shepherd; Dongsheng Tu; Mark Redston; Steven Gallinger
Journal:  N Engl J Med       Date:  2003-07-17       Impact factor: 91.245

9.  The Deyo-Charlson and Elixhauser-van Walraven Comorbidity Indices as predictors of mortality in critically ill patients.

Authors:  Karim S Ladha; Kevin Zhao; Sadeq A Quraishi; Tobias Kurth; Matthias Eikermann; Haytham M A Kaafarani; Eric N Klein; Raghu Seethala; Jarone Lee
Journal:  BMJ Open       Date:  2015-09-08       Impact factor: 2.692

10.  Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.

Authors:  R Dienstmann; M J Mason; F A Sinicrope; A I Phipps; S Tejpar; A Nesbakken; S A Danielsen; A Sveen; D D Buchanan; M Clendenning; C Rosty; B Bot; S R Alberts; J Milburn Jessup; R A Lothe; M Delorenzi; P A Newcomb; D Sargent; J Guinney
Journal:  Ann Oncol       Date:  2017-05-01       Impact factor: 32.976

View more
  1 in total

1.  Is prognosis uniformly excellent in patients with stage II MSI-high colon cancer?

Authors:  Jane Wang; Georgios Antonios Margonis
Journal:  Ann Transl Med       Date:  2022-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.